Cite
HARVARD Citation
Qin, S. et al. (n.d.). P-182Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. Annals of oncology. p. . [Online].